Towards biocompatible vaccine delivery systems: interactions of colloidal PECs based on polysaccharides with HIV-1 p24 antigen.
This work reports on the interactions of a model protein (p24, the capside protein of HIV-1 virus) with colloids obtained from polyelectrolyte complexes (PECs) involving two polysaccharides: chitosan and dextran sulfate (DS). The PECs were elaborated by a one-shot addition of default amounts of one counterpart to the polymer in excess. Depending on the nature of the excess polyelectrolyte, the submicrometric colloid was either positively or negatively charged. HIV-1 capsid p24 protein was chosen as antigen, the ultrapure form, lipopolysaccharide-free (endotoxin-, vaccine grade) was used in most experiments, as the level of purity of the protein had a great impact on the immobilization process. p24 sorption kinetics, isotherms, and loading capacities were investigated for positively and negatively charged particles of chitosans and dextran sulfates differing in degrees of polymerization (DP) or acetylation (DA). Compared with the positive particles, negatively charged colloids had higher binding capacities, faster kinetics, and a better stability of the adsorbed p24. Capacities up to 600 mg x g(-1) (protein-colloid) were obtained, suggesting that the protein interacted within the shell of the particles. Small-angle X-rays scattering experiments confirmed this hypothesis. Finally, the immunogenicity of the p24-covered particles was assessed for vaccine purposes in mice. The antibody titers obtained with immobilized p24 was dose dependent and in the same range as for Freund's adjuvant, a gold standard for humoral responses.
Drogoz
Alexandre
A
Unité Mixte CNRS-BioMérieux, UMR 2714, ENS Lyon, 69364 Lyon Cedex 07, France.
Munier
Séverine
S
Verrier
Bernard
B
David
Laurent
L
Domard
Alain
A
Delair
Thierry
T
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000493:pharmacokinetics; D003102:Colloids / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D049832:Decapodiformes; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D016655:HIV Core Protein p24 / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D011108:Polymers / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D011134:Polysaccharides / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*
D016915:AIDS Vaccines; D001672:Biocompatible Materials; D003102:Colloids; D016655:HIV Core Protein p24; D011108:Polymers; D011134:Polysaccharides; C002189:polyelectrolyte 60